These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30152527)

  • 61. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers.
    Wallace M; White A; Grako KA; Lane R; Cato AJ; Snodgrass HR
    Scand J Pain; 2017 Oct; 17():243-251. PubMed ID: 29229209
    [TBL] [Abstract][Full Text] [Related]  

  • 63. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
    Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
    J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
    Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
    Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The histamine Hâ‚„ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects.
    Kollmeier A; Francke K; Chen B; Dunford PJ; Greenspan AJ; Xia Y; Xu XL; Zhou B; Thurmond RL
    J Pharmacol Exp Ther; 2014 Jul; 350(1):181-7. PubMed ID: 24817035
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
    Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
    Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of the histamine H
    Werfel T; Layton G; Yeadon M; Whitlock L; Osterloh I; Jimenez P; Liu W; Lynch V; Asher A; Tsianakas A; Purkins L
    J Allergy Clin Immunol; 2019 May; 143(5):1830-1837.e4. PubMed ID: 30414855
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
    van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SAGE-217, A Novel GABA
    Hoffmann E; Nomikos GG; Kaul I; Raines S; Wald J; Bullock A; Sankoh AJ; Doherty J; Kanes SJ; Colquhoun H
    Clin Pharmacokinet; 2020 Jan; 59(1):111-120. PubMed ID: 31338688
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
    Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
    Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 75. First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
    Okour M; Gress A; Zhu X; Rieman D; Lickliter JD; Brigandi RA
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1088-1099. PubMed ID: 30950565
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers.
    Noh YS; Yoon S; Kim SR; Lee KT; Jang IJ
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):370-381. PubMed ID: 31125491
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Pharmacology of the Reversible and Potent P2Y
    Juif PE; Boehler M; Dobrow M; Ufer M; Dingemanse J
    J Clin Pharmacol; 2019 Jan; 59(1):123-130. PubMed ID: 30088663
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
    Yang S; Dumitrescu TP
    Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
    Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
    Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.